{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:32:54Z","timestamp":1786699974117,"version":"build-2736575974"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Contemporary national estimates of intrahepatic cholangiocarcinoma (ICC) mortality extending through 2024 are limited. We examined long-term temporal trends and demographic and geographic disparities in ICC mortality among adults in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a serial cross-sectional analysis of the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) Underlying Cause of Death databases. Deaths among US adults aged 25 years or older from 1999 through 2024 were identified using International Classification of Diseases, 10th Revision code C22.1 as the underlying cause of death. Mortality was examined by year, sex, age, race and ethnicity, US Census region, and state from 1999 through 2024; urban\u2013rural analyses were restricted to 1999\u20132020 because later data were unavailable in the extracted database. Crude mortality rates and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Joinpoint regression was used to estimate annual percent changes (APCs) and average annual percent changes (AAPCs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 1999 to 2024, 143,345 ICC deaths were recorded among adults aged 25 years or older. Annual deaths increased from 2,552 to 9,752 (282.13%), and the AAMR rose from 1.44 to 3.35 per 100,000 (AAPC, 3.38%; 95% CI, 3.24%\u20133.52%). In 2024, the AAMR was higher in men than women (3.70 vs 3.11), although the increase was faster in women (AAPC, 3.56% vs 3.15%). Adults aged 85 years or older had the highest crude mortality rate (16.89), whereas those aged 35\u201344 years had the fastest increase (AAPC, 4.13%). Hispanic individuals had the highest AAMR (3.47), while non-Hispanic Black individuals had the largest AAPC (4.03%). The Midwest had both the highest AAMR (3.68) and fastest increase (AAPC, 3.62%). From 1999 to 2020, metropolitan areas had slightly higher AAMRs and faster increases than nonmetropolitan areas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mortality coded to ICC increased substantially in the United States from 1999 through 2024, with marked heterogeneity by sex, age, race and ethnicity, and geography. These descriptive findings distinguish populations with high absolute mortality from those with rapid relative increases, but they do not establish the causes of the observed trends.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1910061","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:52:46Z","timestamp":1786697566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends and disparities in intrahepatic cholangiocarcinoma mortality in the United States, 1999\u20132024: a CDC WONDER analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jianguo","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-025-02038-8","article-title":"Intrahepatic cholangiocarcinoma mortality in the USA, 1999-2020: a 21-year population-based analysis","volume":"36","author":"Khan","year":"2025","journal-title":"Cancer Causes Control"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/10732748211051548","article-title":"Trends in incidence and prognostic factors of two subtypes of primary liver cancers: a Surveillance, Epidemiology, and End Results-based population study","volume":"29","author":"Yao","year":"2022","journal-title":"Cancer Control"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-25","article-title":"Time-trends in liver cancer incidence and mortality rates in the U.S. from 1975 to 2017: a study based on the Surveillance, Epidemiology, and End Results database","volume":"14","author":"Yao","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14701\/ahbps.25-150","article-title":"Updates on incidence, mortality and survival of liver cancer using Korea central cancer registry database: 1999-2022","volume":"29","author":"Hong","year":"2025","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab079","article-title":"The mortality and overall survival trends of primary liver cancer in the United States","volume":"113","author":"Lee","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1715729","article-title":"Shifting mortality patterns of primary liver cancer in the United States: a 20-year analysis of disparities","volume":"13","author":"Zhao","year":"2025","journal-title":"Front Public Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95468","article-title":"Trends in mortality from Malignant neoplasms of the liver and intrahepatic bile ducts in the United States: a retrospective analysis from 1999 to 2020","volume":"17","author":"Talat","year":"2025","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2026.1681142","article-title":"U.S.A. trends in intrahepatic and bile duct cancers from 1999-2023","volume":"5","author":"Berg","year":"2026","journal-title":"Front Gastroenterol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2026.102791","article-title":"Rising liver disease mortality in the United States, 1999-2023: temporal trends and disparities","volume":"50","author":"Wang","year":"2026","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B10","article-title":"An examination of liver cancer incidence in California","volume":"51","author":"Maguire","year":"2024","journal-title":"J Registry Manag"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-024-01955-4","article-title":"Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race\/ethnicity, subsite, and histologic type in the United States from 2000 to 2019","volume":"36","author":"Hsieh","year":"2025","journal-title":"Cancer Causes Control"},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12029-024-01132-5","article-title":"Trends and disparities in intrahepatic cholangiocarcinoma-related mortality in the United States from 1999 to 2020","volume":"56","author":"Rehman","year":"2025","journal-title":"J Gastrointest Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16212","article-title":"Rising mortality of intrahepatic cholangiocarcinoma among older adults in the United States: an analysis of demographic and regional trends","volume":"45","author":"Tariq","year":"2025","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000001258","article-title":"Demographic and regional trends in mortality related to cholangiocarcinoma in the United States: 1999 to 2020","volume":"49","author":"Jamil","year":"2026","journal-title":"Am J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2020.19056","article-title":"Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis","volume":"31","author":"Tan","year":"2020","journal-title":"Turk J Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/cej.0000000000000740","article-title":"Arsenic-contaminated drinking water and cholangiocarcinoma","volume":"32","author":"Reyes","year":"2023","journal-title":"Eur J Cancer Prev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.42451","article-title":"US cancer mortality trends among Asian and Pacific Islander populations","volume":"7","author":"Zhu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002561","article-title":"Racial disparities in liver disease mortality trends among Black and White populations in the United States, 1999-2020: an analysis of CDC WONDER database","volume":"119","author":"Wang","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1472","article-title":"Trends in cancer mortality among Black individuals in the US from 1999 to 2019","volume":"8","author":"Lawrence","year":"2022","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71259","article-title":"Disaggregation of hepatobiliary cancer mortality among Asian Americans: analysis of NVSS mortality data","volume":"14","author":"Park","year":"2025","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf304","article-title":"Trends and projected burden of early-onset gastrointestinal Malignancies in the United States: a population-based analysis (2001-2021)","volume":"118","author":"Yasinzai","year":"2026","journal-title":"J Natl Cancer Inst"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70182","article-title":"Temporal trends in mortality location among patients with intrahepatic cholangiocarcinoma in the USA: a retrospective observational analysis of National Center for Health Statistics mortality data","volume":"9","author":"Nadeem","year":"2025","journal-title":"JGH Open"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1017\/s147895152510031x","article-title":"Trends and disparities in place of death among patients with cholangiocarcinoma: a two-decade analysis","volume":"23","author":"Qureshi","year":"2025","journal-title":"Palliat Support Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2196\/69906","article-title":"The application status of radiomics-based machine learning in intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"27","author":"Xu","year":"2025","journal-title":"J Med Internet Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf016","article-title":"Update for: new developments in systemic therapy for advanced biliary tract cancer","volume":"55","author":"Morizane","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2174\/0929867330666230416152913","article-title":"Futibatinib: a potent and irreversible inhibitor of fibroblast growth factor receptors for treatment of the bile duct cancer","volume":"31","author":"De","year":"2024","journal-title":"Curr Med Chem"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:52:47Z","timestamp":1786697567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1910061"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910061","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1910061"}}